🧾 What This Document Is

This is a 6-K filing, which is a report foreign companies like Israel-based Pulsenmore file with the SEC to announce major news to U.S. investors. This specific report contains their full-year 2025 financial results and a business update. It's essentially their annual press release, packaged for regulators and the market. 👉 The key takeaway: This isn't just a routine report; it's a "state of the union" for investors, highlighting a transformative year driven by a big legal settlement and key regulatory wins.

🏢 What The Company Does

👉 In simple terms, Pulsenmore makes handheld ultrasound devices for home use during pregnancy. Their technology lets expecting mothers perform scans at home under the remote guidance of their doctor, aiming to make prenatal care more convenient and continuous. They are a classic med-tech company, navigating strict regulations (like FDA approvals) to bring new medical devices to market.

💰 Financial Highlights: A Year of Big Changes

The headline numbers show massive growth, but the story behind them is crucial.

Revenue Explosion: Revenue hit $12.5 million in 2025, a 374% increase from $2.6 million in 2024.
The Big Catch: This surge is mostly due to a one-time, $9.6 million payment from a settlement with GE Healthcare (GEHC). Without this, core revenue growth was more modest.
Profitability Path: The net loss shrank dramatically to $5 million from $10 million the year before—a 50% improvement. This shows better control of costs relative to revenue.
Healthy Margins: Gross profit jumped to $10.5 million, with a gross margin of 84%, up from 37%. This means they're keeping much more money from each sale after covering the direct costs of making their devices.
Spending to Grow: Operating expenses rose to $14.4 million as they invested heavily in building their U.S. sales and marketing infrastructure for future growth.

🚀 Key Moves: The GE Settlement & Regulatory Wins

Two major events defined 2025.

The GE Deal: Pulsenmore settled all outstanding disputes with GE Precision Healthcare. This wasn't just about cash—it resolved legal risks and ended old contracts. A chunk of the payment (~$2.2 million) was specifically for canceled orders, turning a potential supply-chain headache into immediate revenue.
U.S. Market Unlock: They secured FDA "De Novo" clearance for their remote-use prenatal ultrasound. This is the golden ticket that allows them to legally sell and market their product in the United States, the world's largest medical device market.
European Expansion: They also received CE Mark certification under new EU regulations, allowing them to sell their "Early-Screening" product across the European Union.

📦 Financial Position: What the Balance Sheet Shows

As of December 31, 2025, the company's financial health looks like this:

Cash & Liquidity: They hold $21.7 million in total liquid assets, with $7 million in pure cash. This is their war chest for commercial expansion.
Shifting Assets: Total assets decreased from ~$44M USD to ~$32M USD. The biggest changes were a significant drop in cash and a rise in inventory (especially non-current inventory), suggesting they are building stock to support future sales.
Managing Liabilities: Total liabilities were cut by more than half, from ~$15.7M to ~$5.9M USD. A large $7.6M contract liability from 2024 (likely related to the GE deal) was cleared off the books.

🔮 What's Next: Commercialization is the Focus

Management’s message is clear: 2025 was about building the foundation (regulations, settlement), and 2026 is about executing. The CEO emphasized:

Accelerating commercial momentum in the U.S.
Increasing utilization of their devices within clinical workflows.
Strengthening recurring revenue streams (potentially from software or per-scan fees).
They are conducting initial U.S. commercial programs to prove their model works before a broader rollout.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:
- Regulatory Moats: FDA and CE clearances are huge barriers to entry for competitors.
- Settlement Windfall: The GE cash infusion de-risks their near-term financials.
- Large Addressable Market: Tapping into the vast and growing prenatal care market in the U.S. and EU.
⚠️ Risks:
- One-Time Boost: The stellar 2025 revenue growth is non-repeatable. Future growth must come from actual device sales.
- Commercial Execution: The biggest challenge now is sales and marketing. Can they convince hospitals and doctors to adopt their new model?
- Cash Burn: While they have a cash cushion, they are still unprofitable and spending heavily to grow.

🧠 The Analogy

Think of Pulsenmore as a talented student who just received a huge, one-time academic scholarship (the GE settlement). This money pays for their final year of school and relieves financial stress. Now, they have to focus entirely on graduating and landing a great job (commercializing their product) to build a successful, self-sustaining career. The scholarship was critical, but their future success depends on their performance in the real world.

📇 Key Contacts & People

Dr. Elazar Sonnenschein: CEO and Founder of Pulsenmore.
Miri Segal-Scharia: Contact for investor relations and annual report requests.
Email: [email protected] (MS-IR LLC)
Company Website: www.pulsenmore.com
Investor Relations: https://pulsenmore.com/investor_relations

🧩 Final Takeaway

Pulsenmore's 2025 was a financially transformative year thanks to a major legal settlement, which provided cash and clarity. Now, the real test begins: converting groundbreaking technology and regulatory approvals into sustained commercial revenue in the competitive U.S. healthcare market. The settlement bought them time and resources; execution in 2026 will determine their long-term trajectory.

Pulsenmore Ltd. — 6-K Filing